Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on August 12, 2024, by Lisata Therapeutics, Inc., a Delaware corporation. The filing serves to disclose the Company's financial results for the second quarter ended June 30, 2024, pursuant to Regulation FD.
Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the detailed financial results are contained in a press release furnished as Exhibit 99.1 and a corporate presentation furnished as Exhibit 99.2, which are incorporated by reference but not included in the text of this 8-K.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the referenced press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing incorporates a corporate presentation (Exhibit 99.2) intended for investor and industry conferences, which may contain outlook or management commentary. However, the text of the 8-K itself does not detail specific guidance, risks, contingencies, or unusual items. The Company notes that the information in Item 7.01 and its exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the specific Q2 2024 financial results (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Review the corporate presentation attached as Exhibit 99.2 for management's outlook and strategic updates.
- Confirm that the financial data in the exhibits is not legally "filed" under Section 18 of the Exchange Act, as noted in the disclosure.
- Check the Nasdaq Capital Market listing status for Common Stock (Symbol: LSTA).